ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Molecular pathways and targeted therapies in colorectal liver metastasis: from bench to bedside.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management.MedComm · 2026Review
- Colorectal cancer liver metastasis: immunosuppressive microenvironment, signaling pathways, and emerging therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal liver metastasis (CRLM) is a major complication of colorectal cancer (CRC), significantly affecting prognosis and survival. Despite advancements in treatment, the management of CRLM remains challenging, primarily due to the complex molecular mechanisms involved. The key molecular pathways that contribute to CRLM development include the Wnt/β-catenin signaling, epidermal growth factor receptor (EGFR), and angiogenesis pathways. These pathways regulate critical processes such as tumor cell proliferation, invasion, and metastasis, and are central to the formation and progression of CRLM. Advances in molecular biology have provided a deeper understanding of these pathways, enabling the development of targeted therapies aimed at improving treatment outcomes. This review presents a detailed analysis of the molecular pathways involved in CRLM, the current status of targeted therapies, and ongoing challenges in the treatment of CRLM. We examine preclinical and clinical developments in targeting these pathways, including Wnt pathway inhibitors, EGFR inhibitors, and anti-angiogenic therapies. In addition, the review discusses ongoing challenges, such as resistance mechanisms, and the potential for combination therapies to improve clinical outcomes. Ultimately, this article highlights the promise of personalized approaches, where molecular profiling can guide therapeutic choices to improve patient outcomes.
Indexed as
Identifiers
40880010What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.